Amalfitano A - Search Results

1

Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector.

Sun B, Chen YT, Bird A, Xu F, Hou YX, Amalfitano A, Koeberl DD. Sun B, et al. Among authors: amalfitano a. Mol Ther. 2003 Apr;7(4):467-77. doi: 10.1016/s1525-0016(03)00022-4. Mol Ther. 2003. PMID: 12727109 Free article.

2

Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction.

Ding E, Hu H, Hodges BL, Migone F, Serra D, Xu F, Chen YT, Amalfitano A. Ding E, et al. Among authors: amalfitano a. Mol Ther. 2002 Apr;5(4):436-46. doi: 10.1006/mthe.2002.0563. Mol Ther. 2002. PMID: 11945071 Free article.

3

Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector.

Sun BD, Chen YT, Bird A, Amalfitano A, Koeberl DD. Sun BD, et al. Among authors: amalfitano a. Mol Ther. 2003 Feb;7(2):193-201. doi: 10.1016/s1525-0016(02)00055-2. Mol Ther. 2003. PMID: 12597907 Free article.

4

Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.

Xu F, Ding E, Migone F, Serra D, Schneider A, Chen YT, Amalfitano A. Xu F, et al. Among authors: amalfitano a. J Gene Med. 2005 Feb;7(2):171-8. doi: 10.1002/jgm.660. J Gene Med. 2005. PMID: 15515143

5

Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.

Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A, Amalfitano A, Chen YT, Koeberl DD. Sun B, et al. Among authors: amalfitano a. Mol Ther. 2005 Jan;11(1):57-65. doi: 10.1016/j.ymthe.2004.10.004. Mol Ther. 2005. PMID: 15585406 Free article.

6

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A, Brown T, Young SP, Clay TM, Amalfitano A, Chen YT, Koeberl DD. Franco LM, et al. Among authors: amalfitano a. Mol Ther. 2005 Nov;12(5):876-84. doi: 10.1016/j.ymthe.2005.04.024. Epub 2005 Jul 6. Mol Ther. 2005. PMID: 16005263 Free article.

7

Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.

Kiang A, Hartman ZC, Liao S, Xu F, Serra D, Palmer DJ, Ng P, Amalfitano A. Kiang A, et al. Among authors: amalfitano a. Mol Ther. 2006 Jan;13(1):127-34. doi: 10.1016/j.ymthe.2005.08.006. Epub 2005 Oct 5. Mol Ther. 2006. PMID: 16169280 Free article.

8

Applications of adenoviral vector-mediated gene transfer in cardiovascular research.

Xu F, Serra D, Amalfitano A. Xu F, et al. Among authors: amalfitano a. Methods Mol Med. 2006;129:209-39. doi: 10.1385/1-59745-213-0:209. Methods Mol Med. 2006. PMID: 17085814

9

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.

Banugaria SG, Patel TT, Mackey J, Das S, Amalfitano A, Rosenberg AS, Charrow J, Chen YT, Kishnani PS. Banugaria SG, et al. Among authors: amalfitano a. Mol Genet Metab. 2012 Apr;105(4):677-80. doi: 10.1016/j.ymgme.2012.01.019. Epub 2012 Jan 28. Mol Genet Metab. 2012. PMID: 22365055 Free PMC article.

10

Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy.

Amalfitano A, Parks RJ. Amalfitano A, et al. Curr Gene Ther. 2002 May;2(2):111-33. doi: 10.2174/1566523024605618. Curr Gene Ther. 2002. PMID: 12109210 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136 results

Search Page